Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05757973 Approved for marketing - Clinical trials for Relapsed or Refractory Multiple Myeloma

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells [white blood cells that produce antibodies] which has returned or difficult to treat) who have relapsed on or are refractory to all locally available and clinically appropriate treatment and who are not eligible for a clinical trial.

NCT ID: NCT05463939 Approved for marketing - Clinical trials for Relapsed or Refractory Multiple Myeloma

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

NCT ID: NCT04534322 Approved for marketing - Clinical trials for Relapsed and/or Refractory Multiple Myeloma

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

sEAPort
Start date: n/a
Phase:
Study type: Expanded Access

To provide early treatment access and evaluate the safety of melflufen and dexamethasone in patients with triple class refractory (TCR) multiple myeloma (MM).

NCT ID: NCT02477891 Approved for marketing - Multiple Myeloma Clinical Trials

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available or available through another protocol for subjects with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD.

NCT ID: NCT01632826 Approved for marketing - Multiple Myeloma Clinical Trials

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

PEXIUS
Start date: n/a
Phase:
Study type: Expanded Access

To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available

NCT ID: NCT01410500 Approved for marketing - Multiple Myeloma Clinical Trials

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.